Fulgent Genetics, Inc.
Key Metrics
- Previous Close
- $24.21
- 52-Week Range
- $13.46 – $31.04
- Market Cap
- $702.11M
- P/E (TTM)
- —
- EPS (TTM)
- -3.10
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.70
- PEG Ratio
- —
- Return on Equity
- -8.74%
- Return on Assets
- -6.68%
- Gross Margin
- 33.82%
- Operating Margin
- -37.09%
- Profit Margin
- -27.53%
- Current Ratio
- 5.34
- Debt/Equity
- 0.01
- Total Debt
- $10.37M
- Free Cash Flow
- $9.73M
- Revenue Growth
- 7.50%
- Earnings Growth
- —
- Enterprise Value
- $413.96M
Market Snapshot
About
Fulgent Genetics, Inc. is a technology company providing comprehensive genetic testing services for physicians, clinicians, and patients to diagnose rare genetic disorders and enable precision medicine. The company offers a broad menu of genetic tests including single-gene testing, multi-gene panels, exome sequencing, and genome sequencing across therapeutic areas such as oncology, reproductive health, cardiology, and neurology. Fulgent significantly expanded its operations during the COVID-19 pandemic by developing and deploying widespread diagnostic testing capabilities, though the company continues to focus on its core genetic testing business. The company operates CLIA-certified and CAP-accredited laboratories utilizing advanced sequencing technologies and bioinformatics platforms.